Glyburide And Metformin Hcl Tablets

Jump to

Zydus Cadila gets USFDA nod for anti-diabetics tablets

"Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Glyburide and Metformin Hcl tablets USP in strengths of 1.25/250, 2.5/500 and 5/500 mg," Cadila Healthcare said in a BSE filing.
Cadila Healthcare rises 3% on USFDA nod for anti-diabetic drug

"Zydus Cadila has received approval from the US Food & Drug Administration to market Glyburide and Metformin Hcl tablets USP in strengths of 1.25/250, 2.5/500 and 5/500 mg," says the company in its filing.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Glyburide And Metformin Hcl Tablets

Zydus Cadila gets USFDA nod for anti-diabetics tablets

Cadila Healthcare rises 3% on USFDA nod for anti-diabetic drug